BUZZ - JPMorgan downgrades HubSpot rating due to "uncertain outlook" amid recovery in revenue growth
路透社2026/10/08 14:17On October 8, JPMorgan downgraded its rating for marketing software company HubSpot (HUBS.N) from “Overweight” to “Neutral,” and also lowered its price target from $268 to $240, which still represents a 23.6% upside from the previous trading day’s closing price. The report pointed out that the timeline for a recovery in revenue growth is “still unclear.” “Although HUBS shares have fallen by more than 40% so far this year, until there are clear signs that the growth slowdown has bottomed out, we do not expect to see renewed investor interest or a significant re-rating of the stock price,” said JPMorgan. Out of 37 brokerages, 13 rate the stock as “Buy” or higher, 23 as “Hold,” and 1 as “Sell”; the median price target is $250, according to Reuters compiled data. Including fluctuations on the day, the stock has declined by 45.2% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be incorrect or lack the intended context; Reuters does not guarantee the accuracy of automated translations and provides them solely for readers' convenience. Reuters assumes no liability for any damages or losses arising from the use of automated translation features.)
October 8 - ** JPMorgan downgraded marketing software company HubSpot (HUBS.N) from “Overweight” to “Neutral”
** The price target was also lowered from $268 to $240 , still implying 23.6% upside compared to the previous trading session’s closing price
** The report noted the “timeline for revenue growth recovery remains unclear”
** “Although HUBS shares have fallen more than 40% so far this year, until clear signs of a bottom in the growth slowdown emerge, we do not expect investor interest to reignite or for the stock price to see a significant re-rating”—JPMorgan
** Among 37 brokerages, 13 rate the stock as “Buy” or higher, 23 as “Hold,” and 1 as “Sell”; the median price target is $250—Reuters compiled data
** After accounting for recent volatility, the stock has declined 45.2% year-to-date
(For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it merely for reader convenience. Reuters assumes no responsibility for any damage or loss caused by the use of automated translation services.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Crypto prices
More
